Pfizer Inc (PFE) 31.23 $PFE
Next-Gen Breast Cancer Drugs Offer Patients Hope
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - 1 hr 32 mins ago
Editor's Note: In the video below, Michael Douglass indicates that only a subset of patients in the phase 1 trial for bemaciclib had breast cancer. All of the patients in the phase 1 trial had breast cancer, but subsets had different types of breast...
Most active New York Stock Exchange-traded stocks
AP - 1 hr 55 mins ago
NEW YORK (AP) ' A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - 1 hr 56 mins ago
NEW YORK (AP) ' Shares of some top pharmaceuticals companies were up at the close of trading:
Teva to Launch Generic Lovaza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:45PM CDT
Teva Pharmaceutical announced that the FDA has approved its generic version of Lovaza.
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 09, 12:16PM CDT
NEW YORK (AP) ' Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Dow Today: Pfizer (PFE) Lower
at The Street - Wed Apr 09, 12:00PM CDT
Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader index with a three-cent decline to $30.84.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Neuroendocrine Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mssxcd/neuroendocrine) has announced the addition of the "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Ipsen S.A. - F. Hoffmann-La Roche Ltd. - Progenics Pharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Threshold Pharmaceuticals, Inc. - Merck & Co., Inc. - Eli Lilly and Company - Daiichi Sankyo Company, Limited - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Stanford University - Grupo Espanol de Tumores Neuroendocrinos - University of Wisconsin Madison - The University of Iowa - University of California, San Francisco - Alberta Health Services Visit http://www.researchandmarkets.com/research/ms...oendocrine
Global Non-Small Cell Lung Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wxkp7j/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - AstraZeneca PLC - Pfizer Inc. - Bristol-Myers Squibb Company - Sanofi - Novartis AG - Merck & Co., Inc. - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - West Japan Oncology Group - European Organization for Research and Treatment of Cancer - Radiation Therapy Oncology Group - Sun Yat-sen University - Eastern Cooperative Oncology Group - Sarah Cannon Research Institute - Barbara Ann Karmanos Cancer Institute For more information visit http://www.researchandmarkets.com/research/wx...small_cell
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
Global Metastatic Breast Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zsqx35/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Breast Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - AstraZeneca PLC - Pfizer Inc. - Sanofi - Bristol-Myers Squibb Company - Johnson & Johnson - Celgene Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Sarah Cannon Research Institute - North Central Cancer Treatment Group - European Organization for Research and Treatment of Cancer - FUDAN University - UCLA's Jonsson Comprehensive Cancer Center - Vanderbilt-Ingram Cancer Center Visit http://www.researchandmarkets.com/research/zs...tic_breast
Global Smoking Cessation and Nicotine De-addiction Products Market 2013 - 2019
M2 - Wed Apr 09, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2qwff/smoking_cessation) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Electronic cigarettes is the largest and the fastest growing segment in the smoking cessation market. Smoking cessation or nicotine de-addiction can be achieved by various modes such as nicotine replacement products, e-cigarettes, anti-depressants and nicotine receptor agonists such as Zyban (bupropion), and Chantix/Champix (varenicline). Smoking de-addiction is also possible with or without assistance of healthcare professionals. The smoking cessation products market has been extensively analyzed on the basis of factors such as the products popularly used, success rate, and geographical reach. This report studies the global smoking cessation and nicotine de-addiction products market from the perspective of various product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. The NRT products market is broadly segmented into nicotine containing gums, transdermal patches, lozenges, sublingual tablets, sprays and nasal inhalers. The prominently used brands for smoking cessation are Zyban and Chantix/Champix which comprise the drug therapy segment of the market. Geographically, the market is analyzed for four major regions, namely North America, Europe, Asia Pacific and Rest of the World (RoW). Each of the segments have been analyzed on the basis of their current and future market size for the period 2011 to 2019, in terms of revenue (USD million), considering 2011 and 2012 as the base years. The compounded annual growth rate (% CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective shares in the smoking cessation and nicotine de-addiction products market for 2012 are provided in this report. Some of the major players profiled for NRT products include Johnson & Johnson, GSK, Pfizer, Takeda Pharmaceuticals Co. Ltd., Cipla, and Revolymer PLC. GSK and Pfizer lead the market for drug therapy while the key players profiled for e-cigarettes market include VMR products, and NJOY. Key Topics Covered: - Introduction - Executive Summary - Global Smoking Cessation and Nicotine De-addiction Market Overview - Global Smoking Cessation and Nicotine De-addiction Products Market, by Product Type - Global Smoking Cessation and Nicotine De-addiction Products Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Cipla Ltd. - GlaxoSmithKline, Inc. - Imperial Tobacco Company of India (ITC Ltd). - McNeil AB - NJOY, Inc. - Novartis International AG - Pfizer, Inc. - Revolymer PLC - Takeda Pharmaceutical Co. Ltd. - VMR Products LLC For more information visit http://www.researchandmarkets.com/research/x2..._cessation
Why Goldman Sachs and Pfizer Held Back the Dow Tuesday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 08, 8:03PM CDT
On Tuesday, the Dow Jones Industrials broke its losing streak, although its gain of just 10 points did little to erase the more than 325 points the Dow had lost on Friday and Monday. Even though broader market measures posted more substantial...
Update on Merck's MK-3475 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:35PM CDT
Merck presented early findings from studies assessing the efficacy of MK-3475.
Many 'Obamacare' critics accepted its subsidies
By CHARLES BABINGTON - AP - Tue Apr 08, 4:09PM CDT
WASHINGTON (AP) ' Several big corporations have reaped millions of dollars from "Obamacare" even as they support GOP candidates who vow to repeal the law. This condemn-while-benefiting strategy angers Democrats, who see some of their top congressional candidates struggling against waves of anti-Obamacare ads partly funded by these companies.
Early Glance: Pharmaceuticals companies
AP - Tue Apr 08, 9:44AM CDT
NEW YORK (AP) ' Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Next-Gen Breast Cancer Drugs Offer Patients Hope
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - 1 hr 32 mins ago
Editor's Note: In the video below, Michael Douglass indicates that only a subset of patients in the phase 1 trial for bemaciclib had breast cancer. All of the patients in the phase 1 trial had breast cancer, but subsets had different types of breast...
Most active New York Stock Exchange-traded stocks
AP - 1 hr 55 mins ago
NEW YORK (AP) ' A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - 1 hr 56 mins ago
NEW YORK (AP) ' Shares of some top pharmaceuticals companies were up at the close of trading:
Teva to Launch Generic Lovaza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:45PM CDT
Teva Pharmaceutical announced that the FDA has approved its generic version of Lovaza.
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 09, 12:16PM CDT
NEW YORK (AP) ' Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Dow Today: Pfizer (PFE) Lower
at The Street - Wed Apr 09, 12:00PM CDT
Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader index with a three-cent decline to $30.84.
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Neuroendocrine Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mssxcd/neuroendocrine) has announced the addition of the "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Ipsen S.A. - F. Hoffmann-La Roche Ltd. - Progenics Pharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Threshold Pharmaceuticals, Inc. - Merck & Co., Inc. - Eli Lilly and Company - Daiichi Sankyo Company, Limited - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Stanford University - Grupo Espanol de Tumores Neuroendocrinos - University of Wisconsin Madison - The University of Iowa - University of California, San Francisco - Alberta Health Services Visit http://www.researchandmarkets.com/research/ms...oendocrine
Global Non-Small Cell Lung Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wxkp7j/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - AstraZeneca PLC - Pfizer Inc. - Bristol-Myers Squibb Company - Sanofi - Novartis AG - Merck & Co., Inc. - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - West Japan Oncology Group - European Organization for Research and Treatment of Cancer - Radiation Therapy Oncology Group - Sun Yat-sen University - Eastern Cooperative Oncology Group - Sarah Cannon Research Institute - Barbara Ann Karmanos Cancer Institute For more information visit http://www.researchandmarkets.com/research/wx...small_cell
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
Global Metastatic Breast Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zsqx35/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Breast Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Breast Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - AstraZeneca PLC - Pfizer Inc. - Sanofi - Bristol-Myers Squibb Company - Johnson & Johnson - Celgene Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Sarah Cannon Research Institute - North Central Cancer Treatment Group - European Organization for Research and Treatment of Cancer - FUDAN University - UCLA's Jonsson Comprehensive Cancer Center - Vanderbilt-Ingram Cancer Center Visit http://www.researchandmarkets.com/research/zs...tic_breast
Global Smoking Cessation and Nicotine De-addiction Products Market 2013 - 2019
M2 - Wed Apr 09, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2qwff/smoking_cessation) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Electronic cigarettes is the largest and the fastest growing segment in the smoking cessation market. Smoking cessation or nicotine de-addiction can be achieved by various modes such as nicotine replacement products, e-cigarettes, anti-depressants and nicotine receptor agonists such as Zyban (bupropion), and Chantix/Champix (varenicline). Smoking de-addiction is also possible with or without assistance of healthcare professionals. The smoking cessation products market has been extensively analyzed on the basis of factors such as the products popularly used, success rate, and geographical reach. This report studies the global smoking cessation and nicotine de-addiction products market from the perspective of various product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. The NRT products market is broadly segmented into nicotine containing gums, transdermal patches, lozenges, sublingual tablets, sprays and nasal inhalers. The prominently used brands for smoking cessation are Zyban and Chantix/Champix which comprise the drug therapy segment of the market. Geographically, the market is analyzed for four major regions, namely North America, Europe, Asia Pacific and Rest of the World (RoW). Each of the segments have been analyzed on the basis of their current and future market size for the period 2011 to 2019, in terms of revenue (USD million), considering 2011 and 2012 as the base years. The compounded annual growth rate (% CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective shares in the smoking cessation and nicotine de-addiction products market for 2012 are provided in this report. Some of the major players profiled for NRT products include Johnson & Johnson, GSK, Pfizer, Takeda Pharmaceuticals Co. Ltd., Cipla, and Revolymer PLC. GSK and Pfizer lead the market for drug therapy while the key players profiled for e-cigarettes market include VMR products, and NJOY. Key Topics Covered: - Introduction - Executive Summary - Global Smoking Cessation and Nicotine De-addiction Market Overview - Global Smoking Cessation and Nicotine De-addiction Products Market, by Product Type - Global Smoking Cessation and Nicotine De-addiction Products Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Cipla Ltd. - GlaxoSmithKline, Inc. - Imperial Tobacco Company of India (ITC Ltd). - McNeil AB - NJOY, Inc. - Novartis International AG - Pfizer, Inc. - Revolymer PLC - Takeda Pharmaceutical Co. Ltd. - VMR Products LLC For more information visit http://www.researchandmarkets.com/research/x2..._cessation
Why Goldman Sachs and Pfizer Held Back the Dow Tuesday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 08, 8:03PM CDT
On Tuesday, the Dow Jones Industrials broke its losing streak, although its gain of just 10 points did little to erase the more than 325 points the Dow had lost on Friday and Monday. Even though broader market measures posted more substantial...
Update on Merck's MK-3475 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:35PM CDT
Merck presented early findings from studies assessing the efficacy of MK-3475.
Many 'Obamacare' critics accepted its subsidies
By CHARLES BABINGTON - AP - Tue Apr 08, 4:09PM CDT
WASHINGTON (AP) ' Several big corporations have reaped millions of dollars from "Obamacare" even as they support GOP candidates who vow to repeal the law. This condemn-while-benefiting strategy angers Democrats, who see some of their top congressional candidates struggling against waves of anti-Obamacare ads partly funded by these companies.
Early Glance: Pharmaceuticals companies
AP - Tue Apr 08, 9:44AM CDT
NEW YORK (AP) ' Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
